Corcept Therapeutics (CORT) Shares Down 1.5%

Corcept Therapeutics Incorporated (NASDAQ:CORT) fell 1.5% during trading on Tuesday . The stock traded as low as $16.68 and last traded at $16.93. 683,156 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 1,105,473 shares. The stock had previously closed at $16.68.

Several brokerages have commented on CORT. Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $30.00 price target on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Stifel Nicolaus assumed coverage on Corcept Therapeutics in a research note on Thursday, August 31st. They issued a “buy” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.20.

The company has a market cap of $1,903.59, a P/E ratio of 57.52 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). The firm had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The company’s quarterly revenue was up 96.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.02 EPS. research analysts forecast that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current fiscal year.

In related news, Director G Leonard Baker, Jr. sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.20% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Suntrust Banks Inc. increased its position in shares of Corcept Therapeutics by 4.0% during the second quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 471 shares during the period. Strs Ohio grew its position in Corcept Therapeutics by 2.0% in the second quarter. Strs Ohio now owns 72,900 shares of the biotechnology company’s stock valued at $860,000 after acquiring an additional 1,400 shares during the period. TIAA CREF Investment Management LLC grew its position in Corcept Therapeutics by 0.7% in the second quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock valued at $4,097,000 after acquiring an additional 2,360 shares during the period. PNC Financial Services Group Inc. grew its position in Corcept Therapeutics by 52.6% in the second quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 3,390 shares during the period. Finally, American International Group Inc. grew its position in Corcept Therapeutics by 8.1% in the third quarter. American International Group Inc. now owns 61,110 shares of the biotechnology company’s stock valued at $1,179,000 after acquiring an additional 4,569 shares during the period. Institutional investors own 64.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Corcept Therapeutics (CORT) Shares Down 1.5%” was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/12/07/corcept-therapeutics-cort-shares-down-1-5.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply